KRAS and non-small cell lung carcinoma: The test yields NCCN-informed results for 15 NSCLC variants across nine genes, representing ~25 targeted treatment modalities, such as a KRAS G12C or EGFR L858R mutation, which could initiate adagrasib or erlotinib immediately rather than waiting for several weeks or more to find the same information from a CGP assay.